New combo therapy aims to cut blood transfusions in bone tumor surgery

NCT ID NCT07314424

Not yet recruiting Disease control Sponsor: Tang Xiaodong Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving a combination of intravenous iron, erythropoietin (EPO), and tranexamic acid before bone tumor surgery can improve hemoglobin levels and reduce the need for blood transfusions compared to usual care. The trial enrolls 160 adults with anemia or iron deficiency who are scheduled for open surgery on the pelvis, spine, or sacrum. The main goal is to measure hemoglobin levels 21 days after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: intravenous ferric derisomaltose (iron), erythropoietin (EPO), and tranexamic acid
What this could lead to: If it works, this could establish a standard blood-management approach for bone tumor patients, reducing the need for blood transfusions and improving recovery.
What could go wrong: This is a single-center, early-phase trial with only 160 participants, so results may not apply broadly. The combination therapy also carries risks like allergic reactions or blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia bone cancer metastatic carcinoma in the bone

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANEMIA

More trials for these conditions

Other studies related to the condition(s) this trial covers.